Fig. 4: Caspase-1 KO in KBP tumors improves the effect of anti-PD1 treatment.
From: Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy
a Growth curves and tumor weights of wild type and caspase-1 KO KBP orthotopic tumors treated with IgG control (n = 18 wild type, 12 caspase-1 KO) or anti-PD1 antibody (n = 16 wild type, 9 caspase-1 KO), **: p = 0.0018; ***: p = 0.0002, ****: p < 0.0001. b Flow cytometric quantification of activated CD8+ T-cells (GrB+ as a proportion of CD8 + PD1+ cells, **: p = 0.0041, n = 7). c Macrophage infiltration quantified by IHC (F4/80 as a proportion of total cells, n = 3). d CD206+ and CD206- cells as a proportion of F4/80+/CD11b+ cells, ****: p < 0.0001, n = 10. e Growth curves and tumor weights of wild type and VX-765 treated KBP orthotopic tumors treated with IgG control or anti-PD1 antibody (n = 6 mice/group), **: p = 0.0023. f Flow cytometric quantification of activated CD8+ T-cells (GrB+ as a proportion of CD8+ PD1+ cells, **: p = 0.0053, n = 9). g Macrophage infiltration quantified by IHC (F4/80 as a proportion of total cells, **: p = 0.0073, n = 3). h CD206+ and CD206- cells as a proportion of F4/80+/CD11b+ cells, n = 6. Mean with SEM, two-way ANOVA with Tukey’s multiple comparisons test for growth curves, one-way ANOVA with Tukey’s multiple comparisons test for tumor weights and macrophage quantification, one-way ANOVA with Dunnett’s multiple comparison test for flow cytometry. ns not significant.
